Fate Therapeutics Inc
NASDAQ:FATE
Fate Therapeutics Inc
Accounts Receivables
Fate Therapeutics Inc
Accounts Receivables Peer Comparison
Competitive Accounts Receivables Analysis
Latest Figures & CAGR of Competitors
Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Fate Therapeutics Inc
NASDAQ:FATE
|
Accounts Receivables
$858k
|
CAGR 3-Years
-50%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Accounts Receivables
$11.9B
|
CAGR 3-Years
8%
|
CAGR 5-Years
16%
|
CAGR 10-Years
13%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accounts Receivables
$4.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
7%
|
CAGR 10-Years
4%
|
|
Amgen Inc
NASDAQ:AMGN
|
Accounts Receivables
$6.8B
|
CAGR 3-Years
15%
|
CAGR 5-Years
12%
|
CAGR 10-Years
10%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accounts Receivables
$1.8B
|
CAGR 3-Years
22%
|
CAGR 5-Years
33%
|
CAGR 10-Years
40%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accounts Receivables
$5.2B
|
CAGR 3-Years
8%
|
CAGR 5-Years
18%
|
CAGR 10-Years
17%
|
See Also
What is Fate Therapeutics Inc's Accounts Receivables?
Accounts Receivables
858k
USD
Based on the financial report for Mar 31, 2024, Fate Therapeutics Inc's Accounts Receivables amounts to 858k USD.
What is Fate Therapeutics Inc's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
11%
Over the last year, the Accounts Receivables growth was -94%. The average annual Accounts Receivables growth rates for Fate Therapeutics Inc have been -50% over the past three years , 11% over the past five years .